Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients

Multiple Sclerosis Journal

Volumn 20, Issue 7, 2014, Pages 837-842

  Jilek, Samantha ^a   Mathias, Amandine ^a   Canales, Mathieu ^a   Lysandropoulos, Andreas ^a   Pantaleo, Giuseppe ^a   Schluep, Myriam ^a   Du Pasquier, Renaud A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adverse effects; Cd11a; Cellular immunity; CXCR3; Integrins; LFA 1; Longitudinal study; Natalizumab; Progressive multifocal encephalopathy; T cell; VLA 4

Indexed keywords

ALPHA1 INTEGRIN; BETA1 INTEGRIN; CD4 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NATALIZUMAB; VERY LATE ACTIVATION ANTIGEN 4; ALPHA4 INTEGRIN; CHEMOKINE RECEPTOR; CORTICOSTEROID; INTEGRIN; BIOLOGICAL MARKER; CCR6 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DOWN REGULATION; EFFECTOR CELL; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; ANTIGEN EXPRESSION; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; LYMPHOCYTE MIGRATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; T LYMPHOCYTE; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BIOMARKERS; CD11A ANTIGEN; CHEMOTAXIS, LEUKOCYTE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTEGRIN ALPHA4BETA1; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; RECEPTORS, CCR6; RECEPTORS, CXCR3; T-LYMPHOCYTE SUBSETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902164192     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513513208     Document Type: Article

References (27)

1. Sospedra M and Martin R. Immunology of multiple sclerosis. Ann Rev Immunol 2005; 23: 683-747 (Pubitemid 40563183)
2. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Discov 2005; 4: 510-518 (Pubitemid 40861993)
3. Coisne C, Mao W and Engelhardt B. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol 2009; 182: 5909-5913
4. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59: 748-754 (Pubitemid 43673152)
5. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59: 743-747 (Pubitemid 43673151)
6. Kivisakk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009; 72: 1922-1930
7. Jilek S, Jaquiery E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: A cross-sectional and longitudinal study. Lancet Neurol 2010; 9: 264-272
8. Berger JR and Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab: Unforeseen consequences. N Engl J Med 2005; 353: 414-416 (Pubitemid 41132348)
9. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880
10. Dustin ML. The cellular context of T-cell signaling. Immunity 2009; 30: 482-492
11. Hirota K, Yoshitomi H, Hashimoto M, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007; 204: 2803-2812 (Pubitemid 350179551)
12. Kleinewietfeld M, Puentes F, Borsellino G, et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005; 105: 2877-2886 (Pubitemid 40446282)
13. Garcia-Lopez MA, Sanchez-Madrid F, Rodriguez-Frade JM, et al. CXCR3 chemokine receptor distribution in normal and inflamed tissues: Expression on activated lymphocytes, endothelial cells and dendritic cells. Lab Investigat 2001; 81: 409-418 (Pubitemid 32245072)
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846 (Pubitemid 41746873)
15. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectin is a possible biomarker for individual PML risk in natalizumabtreated MS patients. Neurology 2013; 81: 865-871
16. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410: 106-111 (Pubitemid 32225845)
17. Jilek S, Schluep M, Rossetti AO, et al. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. Clin Immunol 2007; 123: 105-113 (Pubitemid 46401506)
18. Antoniol C, Jilek S, Schluep M, et al. Impairment of JCVspecific T-cell response by corticotherapy: Effect on PML-IRIS management? Neurology 2012; 79: 2258-2264
19. Harrer A, Wipfler P, Einhaeupl M, et al. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. J Neuroimmunol 2011; 234: 148-154
20. Skarica M, Eckstein C, Whartenby KA, et al. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol 2011; 235: 70-76
21. Groom JR and Luster AD. CXCR3 in T cell function. Exp Cell Res 2011; 317: 620-631
22. Ito T, Carson WF, Cavassani KA, et al. CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res 2011; 317: 613-619
23. Dugger KJ, Zinn KR, Weaver C, et al. Effector and suppressor roles for LFA-1 during the development of experimental autoimmune encephalomyelitis. J Neuroimmunol 2009; 206: 22-27
24. Rothhammer V, Heink S, Petermann F, et al. Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE. J Exp Med 2011; 208: 2465-2476
25. Dubertret L, Sterry W, Bos JD, et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a Phase III international randomized, placebo-controlled trial. Brit J Dermatol 2006; 155: 170-181 (Pubitemid 43876411)
26. Korman BD, Tyler KL and Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: A cautionary tale for dermatologists. Arch Dermatol 2009; 145: 937-942
27. Schwab N, Ulzheimer JC, Fox RJ, et al. Fatal PML associated with efalizumab therapy: Insights into integrin alphaLbeta2 in JC virus control. Neurology 2012; 78: 458-467.